Biotech entity
Of the tracked stories, 2 of 3 also mention Biden Administration, the most common co-covered peer. Each story carries 7.7 original sources on average, compared with 5 for the broader beat in this window. That works out to roughly 0.6 stories per week across a 35-day span.
Last mentioned: Aug 8, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Biden Administration, the most common co-covered peer. Each story carries 7.7 original sources on average, compared with 5 for the broader beat in this window. That works out to roughly 0.6 stories per week across a 35-day span. At 6.7, the average consequence score sits above the same-window beat average of 6.5. fda-approval accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. We currently track 3 Biotech stories that mention Chuck Schumer, published between June 28, 2026 and August 1, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 154 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Chuck Schumer. Shared-story counts are live from our verified record — not editorial picks.
Subsidy Program Ends
The temporary premium subsidy officially concludes; beneficiaries may face higher monthly costs unless insurers absorb the cost or new policies emerge.
2027 Premiums Announced Amid Elections
Part D plan rates for 2027 are released in the fall, coinciding with November midterm elections where cost of living is a top issue.
CMS Announces Subsidy Program Will End
Administrator Dr. Mehmet Oz announces the subsidy will conclude in 2027, citing $3.6B in taxpayer costs for 2026 and a desire to stop subsidizing insurers.
Drug Price Cuts Take Effect
Lower negotiated prices for 10 popular and expensive drugs begin for Part D enrollees, as mandated by the IRA.
Biden Administration Implements Temporary Part D Subsidy
A subsidy program is launched to offset premium increases for Medicare Part D enrollees caused by the IRA’s benefit changes.
Inflation Reduction Act Signed
Legislation includes drug price negotiation and Part D benefit redesign, setting the stage for higher base premiums that later necessitate a temporary subsidy.
The elimination of a $3.6 billion Medicare Part D subsidy may raise drug costs for seniors, potentially reducing adherence and impacting pharmaceutical manufacturers' market outlook. The move adds to pricing pressures from the Inflation Reduction Act.
Source: nbcbayarea.com · nbcnewyork.com
Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Source: orlandosentinel.com · citizensvoice.com
The $1.4 billion Ebola component of the White House’s war funding request could accelerate development of new vaccines and antivirals, offering a rare bright spot for biopharma firms amid broader fiscal uncertainty.
Source: stcatharinesstandard.ca · yahoo.com
Chuck Schumer is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
